• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dentrix Ascend Introduces Next Generation Clinical Workflow Built with AWS

    4/30/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email

    Voice and AI bring charting, imaging, and treatment planning into a single, continuous workflow, helping practices move faster at the chairside and complete more within a single patient visit.

    Henry Schein One, the global leader in dental technology, today announced the launch of its Next Generation Clinical Workflow, a voice-driven, AI-enabled advancement embedded within the Dentrix Ascend platform that transforms how dentistry is delivered at the chairside. The Next Generation Clinical Workflow represents the next step in Henry Schein One's ongoing collaboration with Amazon Web Services (AWS) to bring generative AI into everyday clinical workflows.

    The Next Generation Clinical Workflow brings imaging, charting, diagnostics, and treatment planning into a single, continuous experience. Clinicians can capture data, navigate the system, and complete documentation using voice and AI without breaking focus or leaving the patient. AI-enabled capabilities within the workflow are intended as a detection aid to support dentists and healthcare providers, used alongside clinical findings and practitioner judgment in making final diagnostic and treatment decisions. By enabling doctors to stay in a single pair of gloves, the technology helps improve efficiency and patient engagement during exams and treatment.

    Henry Schein One's dental technology platforms support more than 100,000 global locations, including approximately 90% of the top DSOs, processing over 120 million claims annually. With more than 191 million eligibility checks and 22 million completed digital forms, the scale of structured clinical and operational data inside the platform enables AI to work in real workflows, not in isolation.

    At its core is a simple idea: when clinical workflows work better, practices perform better.

    "For too long, clinicians have had to adapt to software instead of software adapting to how clinicians work," said Dr. Ryan Hungate, Chief Clinical and Strategy Officer, Henry Schein One. "With Next Generation Clinical Workflow, we're embedding intelligence directly into the flow of care, connecting what happens chairside to the operational and financial outcomes that follow."

    The Next Generation Clinical Workflow today includes:

    • Image Verify: Real-time AI review of radiographs helps support image quality, staff training, and cleaner claims through stronger documentation.
    • Voice Notes: Automatically captures and generates structured clinical notes from ambient chairside conversations, saving charting time while supporting clinical accuracy.
    • Voice Perio: Enables hands-free periodontal charting through voice, helping clinicians to document findings quickly and accurately without breaking clinical flow.
    • Detect AI: Through integrated third-party AI diagnostic capabilities powered by Videa, clinicians can surface potential areas of concern as a detection aid to support diagnosis, used alongside clinical judgment and other patient findings.

    Looking ahead, Henry Schein One's vision for the Next Generation Clinical Workflow includes expanding intelligence deeper into the clinical experience through capabilities such as AI-powered image magnification to help better see areas for clinician review, disease progression analysis using heat mapping to highlight changes over time, voice charting that converts spoken findings into structured chart entries in real time, voice command for hands-free navigation across imaging, charting, and workflows, and AI treatment planning coaching to support more effective treatment conversations and help improve case acceptance.

    Together, these innovations point toward a more connected clinical experience where intelligence supports clinicians at every step of care, helping improve consistency, efficiency, and practice performance.

    For DSOs, consistency and scalability are critical across multi-location environments where variation can impact both care and performance.

    "When clinical data, imaging, and AI are fully integrated into one platform, it creates a more standardized and efficient experience across locations," said Dr. AJ Acierno, Chief Clinical Officer, Smile Brands. "That consistency supports better patient outcomes while driving operational performance at scale."

    By connecting insights directly to structured documentation and treatment planning, the workflow helps reduce downstream friction, supporting cleaner claims, faster approvals, and more predictable performance.

    "What stands out in this next phase of Dentrix Ascend is not just the dedication to innovation, but the velocity at which meaningful capabilities are reaching clinicians and their teams," said Dr. Lou Graham, Founder, Catapult Education. "When clinical technology is embedded into everyday workflow in practical ways, it has the potential to improve both the provider and patient experience."

    The launch marks another step in Henry Schein One's broader vision to bring connected, AI-powered workflows into every layer of practice performance.

    To learn more and see a live demo, join Henry Schein One at booth #300 at THRIVELIVE, Henry Schein's premier annual dental education event.

    About Henry Schein One

    Henry Schein One is the global leader in dental technology, delivering integrated solutions that connect practice operations, clinical workflows, and patient experience. Dentrix Ascend is its cloud-based platform built to help practices grow with less complexity. With more than 100,000 global locations on the platform, Henry Schein One provides the infrastructure, the data foundation, the pre-built AI agents, and the open build layer that dental AI runs on. Henry Schein One, LLC, is a joint venture between Henry Schein, Inc. (NASDAQ:HSIC) and Internet Brands.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260429373021/en/

    Media Contact:

    Adam Beeson

    Sr. Manager of Communications, Henry Schein One

    Adam.Beeson@henryscheinone.com

    Get the next $HSIC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    4/16/2026Neutral
    BTIG Research
    4/15/2026$100.00Buy
    Citigroup
    2/23/2026$100.00Neutral → Outperform
    Robert W. Baird
    12/9/2025$86.00Overweight
    Barclays
    8/26/2025$83.00In-line → Outperform
    Evercore ISI
    7/25/2025$75.00Buy → Hold
    Stifel
    7/14/2025$72.00Outperform → Neutral
    Robert W. Baird
    2/14/2025$80.00Equal Weight
    Wells Fargo
    More analyst ratings

    $HSIC
    SEC Filings

    View All

    SEC Form SD filed by Henry Schein Inc.

    SD - HENRY SCHEIN INC (0001000228) (Filer)

    5/29/26 3:04:28 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - HENRY SCHEIN INC (0001000228) (Filer)

    5/22/26 8:00:11 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form DEFA14A filed by Henry Schein Inc.

    DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)

    5/12/26 9:00:08 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Henry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the Board

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14

    5/22/26 8:00:00 AM ET
    $DHR
    $HSIC
    $NVST
    Industrial Machinery/Components
    Industrials
    Medical Specialities
    Health Care

    Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth

    Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution. Across both DSOs and independent practices, the highest-perf

    5/14/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Murphy Kelly Ann claimed ownership of 34,812 shares (SEC Form 3)

    3 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/28/26 5:01:47 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Amendment: Former Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4/A - HENRY SCHEIN INC (0001000228) (Issuer)

    5/26/26 5:16:26 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Bergman Stanley M gifted 50 shares, decreasing direct ownership by 0.02% to 253,279 units (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/22/26 7:03:42 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daniel William K bought $691,900 worth of shares (10,000 units at $69.19) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    5/12/26 4:15:46 PM ET
    $HSIC
    Medical Specialities
    Health Care

    Director Daniel William K bought $670,800 worth of shares (10,000 units at $67.08) (SEC Form 4)

    4 - HENRY SCHEIN INC (0001000228) (Issuer)

    8/11/25 4:26:33 PM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Henry Schein

    BTIG Research initiated coverage of Henry Schein with a rating of Neutral

    4/16/26 8:03:48 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Citigroup initiated coverage on Henry Schein with a new price target

    Citigroup initiated coverage of Henry Schein with a rating of Buy and set a new price target of $100.00

    4/15/26 8:08:55 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Henry Schein from Neutral to Outperform and set a new price target of $100.00

    2/23/26 8:29:17 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    View All

    Henry Schein Enters Exclusive Distribution Agreement for CytoChip's CLIA-Waived Hematology Analyzer

    Partnership Expands Access to FDA-Cleared CitoCBC® System Across the U.S. Henry Schein, Inc. (NASDAQ:HSIC) has entered into a new exclusive distribution agreement with CytoChip Inc. for its flagship product, the CitoCBC® system, a U.S. Food and Drug Administration (FDA) 510(k)-cleared device. Available now to Henry Schein customers in the United States, the CitoCBC system is the first cartridge-based Complete Blood Count (CBC) system to receive a CLIA Waiver, helping expand access to accurate, lab-quality testing at the point of care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115495488/en/CLIA Waived CitoCBC System Des

    1/15/26 10:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Stanley M. Bergman to Retire as Henry Schein's Chief Executive Officer at the End of 2025

    Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan

    7/15/25 7:05:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Financials

    Live finance-specific insights

    View All

    Henry Schein Reports First Quarter 2026 Financial Results

    Q1 2026 GAAP diluted EPS of $0.92 compared to $0.88 GAAP diluted EPS in Q1 2025 Q1 2026 non-GAAP diluted EPS of $1.32 compared to $1.15 non-GAAP diluted EPS in Q1 2025 Reaffirming guidance for 2026 sales, non-GAAP diluted EPS, and Adjusted EBITDA Confirming that value creation initiatives are expected to deliver over $200 million of operating income improvement over the next few years, with $125 million run-rate by year-end 2026 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 28, 2026. "I am pleased with our strong first

    5/5/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET

    Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2026 financial results before the stock market opens on Tuesday, May 5, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Frederick M. Lowery, Chief Executive Officer and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the prese

    4/21/26 6:30:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    Henry Schein Reports Fourth Quarter and Full Year 2025 Financial Results and Introduces 2026 Financial Guidance

    Q4 2025 GAAP diluted EPS of $0.85, compared to $0.74 GAAP diluted EPS in Q4 2024 Q4 2025 non-GAAP diluted EPS of $1.34, compared to $1.19 non-GAAP diluted EPS in Q4 2024 2026 non-GAAP diluted EPS expected to be in the range of $5.23 to $5.37, with total sales growth expected to be 3-5% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter ended December 27, 2025. "Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters. We are pleased with the sales results across all our businesses, particul

    2/24/26 6:00:00 AM ET
    $HSIC
    Medical Specialities
    Health Care

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    11/13/24 3:30:01 PM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Henry Schein Inc.

    SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

    11/12/24 9:32:27 AM ET
    $HSIC
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

    SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

    2/14/24 11:18:57 AM ET
    $HSIC
    Medical Specialities
    Health Care